Pandemic Perspectives: What’s The New Normal For The Business Of Biopharma?

A Biotech Roundtable, Part 2

In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry. 

speech bubbles with Pandemic Perspectives logo
part 2 of a roundtable discussion on the lasting impact of the pandemic

More from COVID-19

More from Scrip